Firm takes fight to hospital superbugs
ATECH company which has developed a product that can rapidly detect the presence of superbugs has secured £300,000 in new funding.
Linear Diagnostics, which is a spin-out company from the University of Birmingham, will use the funding to develop its platform technology into a handheld device.
It will aim to detect bacterial infections and identify what level of resistance they have to the most common antibiotics without the need for laboratory facilities. The device will provide a readout within minutes of sampling.
The first application will be a device for the detection of urinary tract infections.
It will be used in both primary and secondary care where it will help to restrict inappropriate prescriptions and contribute to the fight against antimicrobial resistance.
Although the technology will initially be developed for the medical sector, it will also be used to address the superbug threat in the agriculture, veterinary and defence sectors.
The new capital comes from the Rainbow Seed Fund, an early-stage venture capital fund focused on building UK technology companies.
The investment was matchfunded with an award from the University of Birmingham’s Spinout Investment fund.
Matt Hicks, chief technology officer and founder of Linear Diagnostics, said: “The investment comes at a crucial point for the company.
“We have achieved proof of concept and now have partnerships in place that will steer rapid development in an area of high unmet need which also has a high volume of tests.”
Oliver Sexton, investment director for the Rainbow Seed Fund, said: “Antimicrobial resistance is a global health concern and there is a clear need for new strategies to tackle it. Rapid diagnosis can both curtail the ineffective antibiotic prescribing that fuels antimicrobial resistance and identify the appropriate course of treatment for the individual patient.”